Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma

Journal of Magnetic Resonance Imaging

Volumn 10, Issue 3, 1999, Pages 277-285

  Reddick, Wilburn E ^a,c   Taylor, June S ^a,b   Fletcher, Barry D ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF MEMPHIS   (United States)

Author keywords

Bone neoplasms; Dynamic contrast MR; Therapy efficacy; Tumor microcirculation; Tumor response

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; GADODIAMIDE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE ALBUMIN; GADOLINIUM PENTETATE POLYLYSINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ARTICLE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CONTRAST ENHANCEMENT; DRUG RESPONSE; DRUG TISSUE LEVEL; EXTRACELLULAR SPACE; EXTRAVASCULAR SPACE; HUMAN; INTERSTITIUM; INTRAVENOUS DRUG ADMINISTRATION; MICROCIRCULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SIGNAL NOISE RATIO;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; CONTRAST MEDIA; DISEASE-FREE SURVIVAL; EXTRACELLULAR SPACE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SARCOMA, EWING'S;

EID: 0032863707     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(199909)10:3<277::AID-JMRI8>3.0.CO;2-S     Document Type: Article

References (51)

1. Link MP, Eilber F. Osteosarcoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology, vol 2. Philadelphia: JB Lippincott; 1993. p 841.
2. Horowitz ME, DeLaney TR, Malawer MM, et al. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology, vol 2. Philadelphia: JB Lippincott; 1993. p 795.
3. Jaffe R, Santamaria M, Yunis EJ, et al. The neuroectodermal tumor of bone. Am J Surg Pathol 1984;8:885-898.
4. Fletcher BD. Imaging pediatric bone sarcomas: diagnosis and treatment-related issues. Radiol Clin North Am 1997;35:1477-1494.
5. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-1606.
6. Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979;43:2163-2177.
7. Wellings RM, Davies AM, Pynsent PB, Carter SR, Grimer RJ. The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. Clin Radiol 1994;49:19-23.
8. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977;101:14-18.
9. Picci P, Bacci G, Campanacci D, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy: regional mapping of viable and nonviable tumor. Cancer 1985;56:1515-1521.
10. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol 1983;106:21-24.
11. Raymond AK, Chawla SP, Carrasco CH, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 1987;4:212-236.
12. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-1230.
13. Van der Woude H-J, Bloem JL, Taminiau AHM, Nooy MA, Hogendoorn PCW. Classification of histopathologic changes following chemotherapy in Ewing's sarcoma of bone. Skeletal Radiol 1994;23: 501-507.
14. Verstraete KL, De Deene Y, Roels H, et al. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging - parametric "first-pass" images depict tissue vascularization and profusion. Radiology 1994;192:835-843.
15. Oberlin O, Patte C, Demeocq F, et al. The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. Eur J Cancer Clin Oncol 1985;21:463-467.
16. Picci P, Rougraff BT, Bacci G, et al. Prognostic signifigance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extermities. J Clin Oncol 1993;11:1763-1769.
17. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. Cancer 1992;69:698-708.
18. Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994;12:2699-2705.
19. Hudson M, Jaffe M, Jaffe N, et al. Pediatric osteosarcoma: therapeutic stratagies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 1990;8:1988-1997.
20. Gherlinzoni F, Picci P, Bacci G, Campanacci D. Limb sparing versus amputation in osteosarcoma: correlation between local control, surgical margins, and tumor necrosis - Instituto Rizzoli experience. Ann Oncol 1992;3:23-27.
21. Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology 1990;175:791-796.
22. Holscher HC, Bloem JL, Nooy MA, et al. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. AJR 1990;154:763-769.
23. Holscher HC, Bloem JL, Vanel D, et al. Osteosarcoma: chemotherapy-induced changes in MR imaging. Radiology 1992;182:839-844.
24. Pan G, Raymond AK, Carrasco CH, et al. Osteosarcoma: MR imaging after preoperative chemotherapy. Radiology 1990;174:517-526.
25. Sanchez RB, Quinn SF, Walling A, Estrada J, Greenberg H. Musculoskeletal neoplasms after intraarterial chemotherapy: correlation of MR images with pathologic specimens. Radiology 1990;174:237-240.
26. Onikul E, Fletcher BD, Parham DM, Chen G. Accuracy of MR imaging for estimating intraosseous extent of osteosarcoma. AJR 1996;167:1211-1215.
27. Glazer HS, Lee JKT, Levitt RG, et al. Radiation fibrosis: differentiation from recurrent tumor by MR imaging. Radiology 1985;156:721-726.
28. Lawrence JA, Babyn PS, Chan HSL, et al. Extremity osteosarcoma in childhood: prognostic value of radiologic imaging. Radiology 1993;189:43-47.
29. Verstraete KL, Van der Woude H-J, Hogendoorn PCW, et al. Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications. J Magn Reson Imaging 1996;6:311-321.
30. Reddick WE, Langston JW, Meyer WH, et al. Discrete signal processing of dynamic contrast-enhanced MR imaging: statistical validation and preliminary clinical application. J Magn Reson Imaging 1994;4:397-404.
31. Parker GJM, Suckling J, Tanner SF, et al. Problem tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 1997;7:564-574.
32. Brasch RC, Pham C, Shames DM, et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997;7:68-74.
33. Roberts TPL. Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations. J Magn Reson Imaging 1997;7:82-90.
34. Su M-Y, Muhler A, Lao X, Nalcioglu O. Tumor characterization with dynamic contrast-enhanced MRI using MR contrast agents of various molecular weights. Magn Reson Med 1998;39:259-269.
35. Hittmair K, Gomiscek G, Langenberger K, et al. Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 1994;31:567-571.
36. Rosen BR, Belliveau JW, Chien D. Perfusion imaging by nuclear magnetic resonance. Magn Reson Q 1989;5:263-281.
37. Belliveau JW, Rosen BR, Kantor HL, et al. Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med 1990;14: 538-546.
38. Buxton RB, Frank LR, Wong EC, et al. A general kinetic model for quantitative perfusion imaging with arterial spin-labeling. Magn Reson Med 1998;40:383-396.
39. Brix G, Semmler W, Port R, et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:621-628.
40. Donahue KM, Burstein D, Manning WJ, Gray ML. Studies of Gd-DTPA relaxivity and proton exchange rates in tissue. Magn Reson Med 1994;32:66-76.
41. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101.
42. Tofts PS, Berkowitz BA, Schnall MD. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995;33:564-568.
43. Tofts PS, Berkowitz BA. Measurement of capillary permeability from the Gd enhancement curve: a comparison of bolus and constant infusion injection methods. Magn Reson Imaging 1994;12: 81-91.
44. Erlemann R, Reiser MF, Peters PE, et al. Musculoskeletal neoplasms: static and dynamic Gd-DTPA-enhanced MR imaging. Radiology 1989;171:767-773.
45. Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA. Pediatric musculoskeletal tumors: use of dynamic contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology 1992;184: 243-248.
46. Hanna SL, Parham DM, Fairclough DL, et al. Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping. Invest Radiol 1992;27:367-373.
47. Hanna SL, Reddick WE, Parham DM, et al. Automated pixel-by-pixel mapping of dynamic contrast-enhanced MR images for evaluation of osteosarcoma response to chemotherapy: preliniary results. J Magn Reson Imaging 1993;3:849-853.
48. Kawai A, Sugihara S, Kunisada T, Uchida Y, Inoue H. Imaging assessment of the response of bone tumors to preoperative chemotherapy. Clin Orthop 1997;337:216-225.
49. Reddick WE, Bhargava R, Taylor JS, Meyer WH, Fletcher BD. Dynamic contrast-enhanced MR Imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J Magn Reson Imaging 1995;5:689-694.
50. Bonnerot V, Charpentier A, Frouin F, et al. Factor analysis of dynamic magnetic resonance imaging in predicting the response of osteosarcoma to chemotherapy. Invest Radiol 1992;27: 847-855.
51. Meyers PA, Heller G, Healy J, et al. Chemotherapy for non-metastatic ostegenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.